Canary Merger Holdings Inc

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into a clinical trial agreement with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to ascertain the maximum tolerated dose of eflornithine, while evaluating efficacy and then moving into a Phase II efficacy trial. We anticipate data from the Phase I trial by the end of this year with a look to start the Phase II trial at the end of the year or early 2024.

Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - President & CEO Sue Horvath - VP & CFO Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good day, and welcome to the Panbela Therapeutics first-quarter 2023 earnings call. [Operator Instructions].

Panbela Therapeutics, Inc. (PBLA) Q1 2023 Earnings Call Transcript

MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2023. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q1 2023 Financial Results

Crown ElectroKinetics

Faraday Future Intelligent Electric

Use these tips for swing trading penny stocks The post Mastering the Best Penny Stock Swing Trading Techniques  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Mastering the Best Penny Stock Swing Trading Techniques

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 4, 2023, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023.

Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), taking place April 14-19, 2023. The work reflects the Company's ongoing collaboration with Johns Hopkins University School of Medicine.

Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.

Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.

Panbela (PBLA) Regains Flynpovi Rights to Treat FAP

MINNEAPOLIS, April 12, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase II double-blind, randomized study to evaluate CPP-1X-T (Eflornithine tablets) for recent onset type 1 diabetes. The multi-site clinical trial is led by researchers at Indiana University School of Medicine and funded by JDRF, the leading global type 1 diabetes research and advocacy organization.

First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine

MINNEAPOLIS, April 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that it has regained the North American rights to develop and commercialize Flynpovi (the combination of CPP-1X (eflornithine) and sulindac) in patients with familial adenomatous polyposis (FAP), as a result of the termination of the licensing agreement between Cancer Prevention Pharmaceuticals, Inc. (CPP) and with One-Two Therapeutics Assets Limited.

Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)

MINNEAPOLIS, April 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that an abstract about CPP-1X (also known as DFMO or Eflornithine) research, has been accepted for poster presentation at the Immunology of Diabetes Society (IDS) meeting, which will be held May 23-27, 2023.

Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting

MINNEAPOLIS, April 06, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract about CPP-1X (also known as DFMO or Eflornithine) research, has been accepted for poster presentation at the Endocrine Society meeting, which will be held June 15-18, 2023.

Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine. The collaboration is intended to expand the development of Panbela's investigative agent ivospemin (SBP-101), including activity in models of ovarian and other cancer types, further evaluations into mechanism of action, and potential combination with CPP-1X and standard of care agents.

Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine

Patent developed in collaboration with Syngene International Ltd. Patent developed in collaboration with Syngene International Ltd.

Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good day, everyone. And welcome to the Panbela Therapeutics Fourth Quarter 2022 Earnings Call.

Panbela Therapeutics, Inc. (PBLA) Q4 2022 Earnings Call Transcript

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2022. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results

MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 16, 2023, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2022.

Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023

MINNEAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced its first patient enrolled in South Korea for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at  https://clinicaltrials.gov/ct2/show/NCT05254171  .

Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, March 01, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 14-19, 2023. The work reflects the Company's on-going collaboration with Johns Hopkins University School of Medicine.

Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) --   Panbela Therapeutics, Inc. (Nasdaq: PBLA ), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, primarily as a result of the January 30, 2023 closing of its public offering of approximately $15 million of common stock and warrants, Panbela has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”).

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 6,675,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 13,350,000 shares of its common stock (the “Public Warrants”) at a purchase price of $2.25 per share and associated Public Warrant. The Public Warrants will have an exercise price of $2.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about January 30, 2023, subject to customary closing conditions.

Panbela Announces Pricing of Approximately $15 Million Public Offering

MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has issued the Adoption of Commission Implementing Decision relating to the designation of ivospemin (SBP-101) as an orphan medicinal product in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDA). The Commission adopted the decision on January 13, 2023 and it will be published for information in all official languages of the EU in the Community Register of Orphan Medicinal Products (http://ec.europa.eu/health/documents/community-register/html/orphreg.htm). Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to SBP-101.

Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) --  -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announced and stockholder approved 1-for-40 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 13, 2023, and the company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “PBLA.” The CUSIP number for the common stock following the reverse stock split will be 69833W206.

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

MINNEAPOLIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it has commenced a Phase II double-blind, randomized study to evaluate CPP-1X-T (Eflornithine tablets) for recent onset type 1 diabetes, in collaboration with Indiana University School of Medicine and funded by JDRF, the leading global type 1 diabetes research and advocacy organization.

Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pa nbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on Panbela's application for orphan designation of ivospemin (SBP-101) in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDA). Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to SBP-101.

Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

News for Canary Merger Holdings Inc Stock (PBLA)